A citation-based method for searching scientific literature

Romain Varnier, Olivia Le Saux, Sylvie Chabaud, Gwenaëlle Garin, Emilie Sohier, Qing Wang, Sandrine Paindavoine, David Pérol, Christian Baudet, Valéry Attignon, Daniel Pissaloux, Pierre Heudel, Benoit You, Cécile Leyronnas, Olivier Collard, Olivier Trédan, Nathalie Bonnin, Jérôme Long, Jean-Philippe Jacquin, Philippe A Cassier, Olfa Derbel, Gilles Freyer, Alain Viari, Jean-Yves Blay, Isabelle Ray-Coquard. Eur J Cancer 2019
Times Cited: 5







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
60


Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
609
40

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
66
40

Initiation of a formalized precision medicine program in gynecologic oncology.
Camille C Gunderson, Michelle R Rowland, Deborah L Wright, Kelsi L Andrade, Robert S Mannel, D Scott McMeekin, Kathleen N Moore. Gynecol Oncol 2016
12
40

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
327
40


Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
I Ray-Coquard, P Morice, D Lorusso, J Prat, A Oaknin, P Pautier, N Colombo. Ann Oncol 2018
70
20

Limits to Personalized Cancer Medicine.
Ian F Tannock, John A Hickman. N Engl J Med 2016
213
20


Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, Stuart Horswell, M Math, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart,[...]. N Engl J Med 2012
20

Is the NCI MATCH trial a match for gynecologic oncology?
Kathleen N Moore, Robert S Mannel. Gynecol Oncol 2016
15
20

Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
Yong Jae Lee, Dachan Kim, Hyun Soo Kim, Kiyong Na, Jung Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim. Yonsei Med J 2019
7
20


Trastuzumab treatment in breast cancer.
Filippo Montemurro, Giorgio Valabrega, Massimo Aglietta. N Engl J Med 2006
9
20

The Precision of Evidence Needed to Practice "Precision Medicine".
David J Hunter, Dan L Longo. N Engl J Med 2019
11
20

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Michael Friedlander, Val Gebski, Emma Gibbs, Lucy Davies, Ralph Bloomfield, Felix Hilpert, Lari B Wenzel, Daniel Eek, Manuel Rodrigues, Andrew Clamp,[...]. Lancet Oncol 2018
81
20

Precision oncology: neither a silver bullet nor a dream.
Nora S Sánchez, Gordon B Mills, Kenna R Mills Shaw. Pharmacogenomics 2017
14
20

Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Ryusuke Murakami, Noriomi Matsumura, Masaki Mandai, Kosuke Yoshihara, Hiroshi Tanabe, Hidekatsu Nakai, Koji Yamanoi, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi,[...]. Am J Pathol 2016
44
20


Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Gottfried E Konecny, Chen Wang, Habib Hamidi, Boris Winterhoff, Kimberly R Kalli, Judy Dering, Charles Ginther, Hsiao-Wang Chen, Sean Dowdy, William Cliby,[...]. J Natl Cancer Inst 2014
206
20

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Filip Janku, Jennifer J Wheler, Shannon N Westin, Stacy L Moulder, Aung Naing, Apostolia M Tsimberidou, Siqing Fu, Gerald S Falchook, David S Hong, Ignacio Garrido-Laguna,[...]. J Clin Oncol 2012
348
20


Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Robert J Morgan, Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Kian Behbakht, Lee-May Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo,[...]. J Natl Compr Canc Netw 2016
202
20

Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Masataka Takenaka, Motonobu Saito, Reika Iwakawa, Nozomu Yanaihara, Misato Saito, Mamoru Kato, Hitoshi Ichikawa, Tatsuhiro Shibata, Jun Yokota, Aikou Okamoto,[...]. Int J Oncol 2015
13
20

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
423
20

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
931
20



Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Roel G W Verhaak, Pablo Tamayo, Ji-Yeon Yang, Diana Hubbard, Hailei Zhang, Chad J Creighton, Sian Fereday, Michael Lawrence, Scott L Carter, Craig H Mermel,[...]. J Clin Invest 2013
374
20

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Ali Bashashati, Gavin Ha, Alicia Tone, Jiarui Ding, Leah M Prentice, Andrew Roth, Jamie Rosner, Karey Shumansky, Steve Kalloger, Janine Senz,[...]. J Pathol 2013
272
20


Next-generation sequencing to guide cancer therapy.
Jeffrey Gagan, Eliezer M Van Allen. Genome Med 2015
164
20

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
A Spreafico, A M Oza, B A Clarke, H J Mackay, P Shaw, M Butler, N C Dhani, S Lheureux, M K Wilson, S Welch,[...]. Gynecol Oncol 2017
17
20


Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
20

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook,[...]. Cancer Res 2016
150
20

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
20

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Mariacarmela Santarpia, Tommaso Martino De Pas, Giuseppe Altavilla, Lorenzo Spaggiari, Rafael Rosell. Future Oncol 2013
8
20

Improving treatment results with reference centres for rare cancers: where do we stand?
Isabelle Ray-Coquard, Eric Pujade Lauraine, Axel Le Cesne, Patricia Pautier, Marie Cecile Vacher Lavenue, Annalisa Trama, Paolo Casali, Jean Michel Coindre, Jean Yves Blay. Eur J Cancer 2017
25
20


From theoretical synergy to clinical supra-additive toxicity.
Jean-Charles Soria, Christophe Massard, Hassane Izzedine. J Clin Oncol 2009
32
20

Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts,[...]. Nature 2013
20


Next-generation sequencing in the clinic: promises and challenges.
Jiekun Xuan, Ying Yu, Tao Qing, Lei Guo, Leming Shi. Cancer Lett 2013
161
20

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.
Markus Kieler, Matthias Unseld, Daniela Bianconi, Fredrik Waneck, Robert Mader, Fritz Wrba, Thorsten Fuereder, Christine Marosi, Markus Raderer, Philipp Staber,[...]. ESMO Open 2019
3
33

The Gynecologic Cancer Intergroup (GCIG): history and current status.
J B Vermorken, E Avall-Lundqvist, J Pfisterer, M Bacon. Ann Oncol 2005
6
20

The value of research collaborations and consortia in rare cancers.
Jean-Yves Blay, Jean-Michel Coindre, Françoise Ducimetière, Isabelle Ray-Coquard. Lancet Oncol 2016
59
20


Clinical trial methodology in rare gynecologic tumor research: Strategies for success.
Jubilee Brown, R Wendel Naumann, William E Brady, Robert L Coleman, Kathleen N Moore, David M Gershenson. Gynecol Oncol 2018
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.